Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchIMMUNOLOGY

touchPANEL DISCUSSION for touchIMMUNOLOGY Listen to leading experts discuss the serious consequences of severe type 2 asthma, how endotyping and biomarkers can help guide treatment selection in such patients, and how recent data and clinical guidelines can inform the long-term management of patients with severe type 2 asthma. The experts Dr Katharine Woessner, Scripps Clinic Medical Group, San Diego, CA, USA Prof. Louis-Philippe Boulet, Laval University, Quebec City, Canada  Prof. Arnaud Bourdin, Arnaud de Villeneuve Hospital, Montpellier, France This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchimmunologyime.org/endotypes-for-treatment-selection-in-severe-T2-asthma/